STOCK TITAN

Verrica (NASDAQ: VRCA) CEO buys 25,000 shares in August

(High)
(Positive)
Form Type
4

Rhea-AI Filing Summary

Verrica Pharmaceuticals Inc. (VRCA) reported that CEO and President Jayson Rieger purchased common stock in the open market. On August 17, 2026, he bought 5,000 shares at $4.91 per share. On August 14, 2026, he bought 20,000 shares at a weighted average price of $5.06 per share, in multiple trades ranging from $5.04 to $5.088. He also reports 15 shares held indirectly by a child and additional shares held in separate family trusts, for which he disclaims beneficial ownership.

Positive

  • None.

Negative

  • None.

Insights

Analyzing...

Insider Rieger Jayson
Role CEO and President
Bought 25,000 shs ($126K)
Type Security Shares Price Value
Purchase Common Stock 5,000 $4.91 $25K
Purchase Common Stock F1 20,000 $5.06 $101K
holding Common Stock -- -- --
holding Common Stock F2 -- -- --
holding Common Stock F2 -- -- --
holding Common Stock F2 -- -- --
Holdings After Transaction: Common Stock — 207,593 shares (Direct); Common Stock — 15 shares (Indirect, By child); Common Stock — 690 shares (Indirect, By trust)
Footnotes (2)
  1. F1. The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.04 to $5.088 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
  2. F2. These shares are held in separate trusts for the benefit of the Reporting Person's immediate family members. The Reporting Person is a co-trustee of each trust. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
Shares purchased (Aug 17, 2026) 5,000 shares Open-market purchase of Verrica common stock by CEO Jayson Rieger at $4.91 per share
Purchase price (Aug 17, 2026) $4.91 per share Price paid for 5,000 Verrica common shares
Shares purchased (Aug 14, 2026) 20,000 shares Open-market purchases of Verrica common stock by CEO Jayson Rieger
Weighted average price (Aug 14, 2026) $5.06 per share Weighted average for 20,000 shares bought in multiple transactions
Price range (Aug 14, 2026 trades) $5.04 to $5.088 per share Range of prices for the 20,000-share purchase on August 14, 2026
Indirect holding by child 15 shares Common stock reported as indirectly owned by a child after August 14, 2026
Total net shares bought 25,000 shares Net buy across reported August 2026 transactions in Verrica common stock
weighted average price financial
"The price reported is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
indirect financial
"Common Stock transaction_type holding ownership_type indirect"
beneficial ownership financial
"The Reporting Person disclaims beneficial ownership of these securities"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
Section 16 regulatory
"beneficial owner of these securities for purposes of Section 16"
Section 16 is a U.S. securities law rule that governs the trading and disclosure obligations of company insiders — typically officers, directors and large shareholders — to promote transparency and deter unfair profit-taking. It requires insiders to publicly report their stock trades and allows companies or the issuer to reclaim quick, short-term profits from certain insider trades, like a scoreboard and a refund policy that help investors see and limit possible insider advantage.
open market or private transaction financial
"Purchase in open market or private transaction"

FAQ

What insider buying did VRCA report by CEO Jayson Rieger in this Form 4?

Verrica Pharmaceuticals reported that CEO Jayson Rieger purchased 25,000 shares of common stock in open-market transactions. He bought 20,000 shares on August 14, 2026, and 5,000 shares on August 17, 2026, at per-share prices around $5.

At what prices did the VRCA CEO purchase shares in August 2026?

Jayson Rieger bought 5,000 VRCA shares at $4.91 on August 17, 2026. On August 14, 2026, he purchased 20,000 shares at a $5.06 weighted average price, with individual trade prices ranging from $5.04 to $5.088 per share.

How many VRCA shares did the CEO buy in total according to this Form 4?

According to the filing, CEO Jayson Rieger purchased a total of 25,000 shares of Verrica Pharmaceuticals common stock. This includes 20,000 shares bought on August 14, 2026, and 5,000 shares bought on August 17, 2026, in open-market transactions.

Does the VRCA CEO hold any shares indirectly through family members or trusts?

The filing reports 15 shares of Verrica common stock held indirectly by a child and additional shares held in separate family trusts. Jayson Rieger is a co-trustee of those trusts and disclaims beneficial ownership of the trust-held securities.

Were the August 14, 2026 VRCA share purchases at a single price or multiple prices?

The August 14, 2026 purchases used a weighted average price of $5.06 per share. The 20,000 shares were bought in multiple transactions at prices ranging from $5.04 to $5.088, as disclosed in the footnote to the transaction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Rieger Jayson

(Last)(First)(Middle)
C/O VERRICA PHARMACEUTICALS INC.
44 W. GAY ST., SUITE 400

(Street)
WEST CHESTER PENNSYLVANIA 19380

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Verrica Pharmaceuticals Inc. [ VRCA ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
XOfficer (give title below)Other (specify below)
CEO and President
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
08/14/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock08/14/2026P20,000A$5.06(1)202,593D
Common Stock08/17/2026P5,000A$4.91207,593D
Common Stock15IBy child
Common Stock230IBy trust(2)
Common Stock230IBy trust(2)
Common Stock230IBy trust(2)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.04 to $5.088 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
2. These shares are held in separate trusts for the benefit of the Reporting Person's immediate family members. The Reporting Person is a co-trustee of each trust. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
/s/ Jayson Rieger08/18/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)